GlassScriptPhysician profile
Semaan M Abboud
NPI 1063477529
$5,041.92
in general payments reported to CMS, 2019-2025
27 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $472 · 2021: $991 · 2022: $738 · 2023: $716 · 2024: $577 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $922.05 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $885.38 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $594.74 | 2019-2021 | |
| Ardelyx, INC. | $534.65 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $369.57 | 2021-2024 | Taltz, Olumiant, Zepbound |
| Olympus America INC. | $329.39 | 2020 | |
| Janssen Biotech, INC. | $236.09 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $232.56 | 2019-2022 | |
| Abbott Laboratories | $147.20 | 2022-2023 | Proclaim |
| Idorsia Pharmaceuticals US INC | $139.00 | 2022-2023 | Quviviq |
| Abbvie INC. | $120.90 | 2021-2025 | |
| Ucb, INC. | $102.13 | 2024-2025 | Bimzelx |
| Exact Sciences Corporation | $88.90 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Tactile Systems Technology INC | $58.83 | 2025 | Flexitouch Plus, Nimbl |
| Sunovion Pharmaceuticals INC. | $41.82 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.49 | 2023-2024 | Libtayo |
| Biohaven Pharmaceuticals, INC. | $26.60 | 2021 | |
| Medtronic USA, INC. | $25.10 | 2020 | |
| Celgene Corporation | $23.65 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.16 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2025 | |
| Eisai INC. | $16.93 | 2020 | |
| Glaxosmithkline, LLC. | $16.06 | 2022 | |
| Phadia US INC. | $14.81 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $14.05 | 2019 | |
| Braintree Laboratories, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Semaan Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.